News Release: July 17, 2025
Hexamethylenetetramine (Urotropine) Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
The price trend of Hexamethylenetetramine (Urotropine) over the past five years has been shaped by a combination of industrial demand, raw material price fluctuations, regulatory changes, and global economic disruptions. Between 2019 and 2024, the market has experienced several notable shifts in pricing, largely driven by supply chain constraints, geopolitical tensions, and changes in energy prices.
In 2019, the average global price of Hexamethylenetetramine (Urotropine) hovered around $1,100/MT. The year was relatively stable, with moderate demand from the chemical, plastics, and pharmaceutical industries. Production levels were consistent, and raw materials like formaldehyde and ammonia were available at standard rates.
The situation changed drastically in 2020 when the COVID-19 pandemic disrupted global supply chains. Lockdowns and factory closures led to a dip in production while demand in healthcare-related applications surged. Prices rose to an average of $1,320/MT by the end of the year. The surge was not only due to demand pressure but also logistical issues that affected the transportation of chemical raw materials across international borders.
In 2021, the Hexamethylenetetramine (Urotropine) price trend continued its upward climb, reaching approximately $1,450/MT during the third quarter. This was due to rising energy costs and a global shortage of ammonia. Additionally, heightened demand from downstream industries, including plastics and explosives manufacturing, placed added stress on supply chains. The price increase triggered a temporary expansion in production capacities in parts of Asia and the Middle East.
By 2022, stabilization efforts were underway. New production facilities became operational in India and Southeast Asia, which helped balance supply. However, geopolitical conflicts such as the Russia-Ukraine war impacted energy prices and global chemical markets. Prices briefly spiked to $1,600/MT in the second quarter of 2022 before settling back to around $1,380/MT by the year-end.
In 2023, the Hexamethylenetetramine (Urotropine) price trend indicated a moderate correction due to improved logistics and raw material availability. Average prices stayed within the $1,250–$1,350/MT range. Governments in Asia and Europe also revised their chemical safety norms, pushing manufacturers toward cleaner and more efficient production methods. These upgrades briefly affected production but were essential for long-term cost efficiency and compliance.
Overall, Hexamethylenetetramine (Urotropine) price news over these five years was influenced by a web of factors—energy prices, ammonia and formaldehyde availability, regulatory shifts, and industrial demand from sectors like pharmaceuticals and rubber manufacturing.
The most consistent takeaway from the five-year trend is the resilience of the Hexamethylenetetramine (Urotropine) production sector. Despite global crises, the market adapted by expanding production facilities, improving storage and transportation methods, and fostering stronger inter-regional trade.
Hexamethylenetetramine (Urotropine) Price, Production, Latest News and Developments in 2025
Hexamethylenetetramine (Urotropine) price trend and production News
Hexamethylenetetramine (Urotropine) Price Trend Quarterly Update in $/MT (2024–2025 Estimate)
Here is an estimated quarterly Hexamethylenetetramine (Urotropine) price trend projection from Q1 2024 through Q1 2025:
- Q1 2024: $1,280/MT
- Q2 2024: $1,310/MT
- Q3 2024: $1,295/MT
- Q4 2024: $1,325/MT
- Q1 2025: $1,340/MT
The slight increase projected for Q1 2025 can be attributed to rising demand in Asia-Pacific and restocking needs from European markets. Seasonal production maintenance shutdowns may also temporarily tighten supply in early 2025.
The quarterly Hexamethylenetetramine (Urotropine) price trend indicates stability with marginal upward pressure expected due to stronger end-user demand and slight raw material cost increases. Manufacturers are also implementing sustainable practices, which may influence production costs in upcoming quarters.
Global Hexamethylenetetramine (Urotropine) Import-Export Business Overview
The global Hexamethylenetetramine (Urotropine) trade landscape is diverse, with multiple countries acting as production hubs and a wide network of export destinations. Leading exporters include China, India, Germany, and the Netherlands, while major importers include the United States, Brazil, Japan, and several European Union member states.
In terms of production, China continues to lead global output, accounting for approximately 40% of total Hexamethylenetetramine (Urotropine) production. China’s dominance is rooted in low-cost manufacturing, access to abundant raw materials, and well-developed export logistics. India is emerging as a strong competitor, investing in new facilities that not only expand production capacity but also adhere to international safety and environmental standards.
Hexamethylenetetramine (Urotropine) sales volume has increased steadily, especially post-2021. The average annual global sales volume is estimated to be over 600,000 MT, with a growth rate of 4% year-on-year. This growth is driven by its use in fuel tablets, pharmaceuticals, plastic additives, and explosives. Asia-Pacific represents the largest consumer base due to the expanding chemical and pharmaceutical sectors.
On the export front, China’s share remains unmatched. In 2024, China exported more than 180,000 MT of Hexamethylenetetramine (Urotropine), valued at over $240 million. India’s export numbers crossed 75,000 MT, as the country continues to strengthen its presence in the Middle East and African markets.
The United States and Germany are notable importers. The U.S. imported over 60,000 MT in 2024, mainly for applications in resins and pharmaceuticals. Import patterns are influenced by production costs, environmental regulations, and strategic stockpiling to avoid future supply shocks.
European countries, under stricter REACH regulations, have reduced domestic production and increased reliance on imports. Germany and France, in particular, have imported higher volumes of Hexamethylenetetramine (Urotropine) over the past two years. Importers are now more focused on sourcing from countries with clean and certified production facilities, affecting the trade dynamics.
The latest Hexamethylenetetramine (Urotropine) news in 2025 includes the development of a new bio-based production route under pilot testing in Finland, which could eventually reshape sourcing strategies. If successful, this sustainable pathway may bring down environmental compliance costs and introduce a premium-priced, green-grade product for specialized industries.
Moreover, a notable trade event occurred in early 2025 with the imposition of higher tariffs by the U.S. on Chinese chemical imports, including Hexamethylenetetramine (Urotropine). This development has led U.S. buyers to increase orders from Indian and Southeast Asian suppliers. As a result, Indian exports have spiked by 12% in the first quarter of 2025 alone.
On the logistics side, the Red Sea shipping disruptions in late 2024 had a temporary impact on lead times and shipping costs, particularly for European and North African importers. Although routes have normalized, many exporters are now diversifying shipping lines and ports to mitigate future risks.
In terms of domestic production, South Korea and Japan are investing in niche-grade Hexamethylenetetramine (Urotropine) facilities, aimed at producing ultra-high purity material for use in semiconductor and specialty chemical sectors. These initiatives are expected to be operational by mid-2026, altering regional trade balances.
Looking at pricing, import-dependent countries have experienced slightly higher procurement costs due to currency fluctuations and freight charges. The average CIF price in Europe for Hexamethylenetetramine (Urotropine) in Q1 2025 was $1,420/MT, whereas FOB China prices remained around $1,340/MT. This differential highlights the impact of logistics and tariff structures on international trade.
The Hexamethylenetetramine (Urotropine) price news further indicates that despite market challenges, global trade remains active and dynamic. New trade routes, increased demand from niche applications, and sustainable production practices are shaping the market trajectory. Strategic collaborations between manufacturers and end-users are also on the rise, ensuring steady supply chains and improved product quality.
As the market continues to evolve in 2025, businesses are advised to monitor the Hexamethylenetetramine (Urotropine) price trend closely and stay updated on regulatory and logistical developments. Importers should also diversify sourcing strategies to manage risks associated with geopolitical and environmental disruptions.
For more detailed insights, trends, and a sample report, visit:
Hexamethylenetetramine (Urotropine) Production Trends by Geography
The production of Hexamethylenetetramine (Urotropine) has seen significant shifts globally, shaped by regional advantages, raw material access, policy frameworks, and demand from downstream sectors. As of 2025, the leading producers of Hexamethylenetetramine (Urotropine) include China, India, Germany, Russia, the United States, and a growing presence in Southeast Asia and the Middle East.
China
China remains the dominant producer of Hexamethylenetetramine (Urotropine) in the world. The country benefits from large-scale chemical manufacturing zones, consistent availability of raw materials such as formaldehyde and ammonia, and well-developed logistics infrastructure. Chinese producers also gain from economies of scale and flexible manufacturing systems. More than 40% of the global Hexamethylenetetramine (Urotropine) output originates from China, with significant volumes exported to Europe, North America, and Southeast Asia.
Recent trends show increased investment in environmentally sustainable production technologies in China. Many producers are upgrading to continuous production systems to improve efficiency and reduce emissions. Additionally, China’s internal demand from rubber, pharmaceuticals, and plastic industries continues to drive domestic consumption.
India
India has emerged as a strong competitor in Hexamethylenetetramine (Urotropine) production. With chemical parks expanding in Gujarat and Maharashtra, the country has significantly increased its capacity over the last five years. Indian manufacturers focus on both bulk-grade and pharmaceutical-grade Hexamethylenetetramine (Urotropine), with exports growing particularly toward Africa, Southeast Asia, and the Middle East.
The Indian government’s focus on boosting the domestic chemical industry through incentives and simplified regulations has further supported the expansion of Hexamethylenetetramine (Urotropine) production facilities. Local raw material availability and a skilled labor force contribute to India’s rising role as a global supplier.
Germany
Germany is one of Europe’s largest producers of Hexamethylenetetramine (Urotropine), mainly focused on high-purity grades used in pharmaceuticals and industrial resins. German facilities are recognized for their quality compliance, adherence to EU environmental norms, and advanced R&D integration. However, rising energy costs and stringent environmental regulations have somewhat limited expansion efforts in recent years.
Despite these challenges, Germany continues to supply key EU markets and maintains a steady export profile. Producers in Germany are also investing in recycling technologies and greener alternatives to traditional chemical feedstocks.
Russia
Russia’s Hexamethylenetetramine (Urotropine) production is primarily aligned with domestic consumption, especially in explosives and industrial sectors. Large chemical complexes in western Russia produce considerable volumes, but exports are limited due to geopolitical constraints and trade restrictions. Despite facing logistical and financial barriers, Russia continues to maintain its production levels through state-backed chemical entities.
United States
The United States has seen moderate Hexamethylenetetramine (Urotropine) production, mainly intended for pharmaceutical and resin applications. Domestic production is supported by steady raw material supply and high automation. However, compared to Asia, the U.S. faces higher production costs and relatively limited production capacity. Imports from Asia, especially India and China, supplement the domestic supply to meet market demand.
Southeast Asia and Middle East
Countries such as Indonesia, Vietnam, and Saudi Arabia are increasingly investing in chemical production capacities, including Hexamethylenetetramine (Urotropine). Saudi Arabia, with its abundant natural gas reserves and downstream industrial plans under Vision 2030, is exploring capacity development in specialty chemicals.
Southeast Asian nations are benefiting from trade agreements, low labor costs, and proximity to large markets. New plants have begun production, aimed at serving regional demand and reducing dependency on Chinese imports.
Overall, the global Hexamethylenetetramine (Urotropine) production landscape in 2025 reflects both consolidation in traditional regions and diversification into emerging markets. Environmental compliance, cost-efficiency, and proximity to end-use industries are the key drivers shaping regional production strategies.
Hexamethylenetetramine (Urotropine) Market Segmentation
Key Market Segments:
- By Application
- By End-Use Industry
- By Purity Grade
- By Distribution Channel
- By Geography
By Application:
- Plastics and Rubber Additives
- Pharmaceuticals
- Explosives (RDX production)
- Fuel Tablets
- Resin and Coatings
- Water Treatment Chemicals
- Laboratory Reagents
The plastics and rubber additives segment holds a significant share in Hexamethylenetetramine (Urotropine) sales volume. This is due to its widespread use as a curing agent in phenolic resins and as a cross-linking agent in rubber. Its ability to improve thermal stability and mechanical strength in molded parts has made it indispensable in automotive and industrial applications.
Pharmaceutical applications represent another important segment, especially in the production of urinary antiseptics. Pharmaceutical-grade Hexamethylenetetramine (Urotropine) is subject to strict purity controls, and this segment commands premium pricing due to quality requirements.
In explosives manufacturing, Hexamethylenetetramine (Urotropine) is a precursor in the synthesis of RDX and other nitroamines. Defense sectors in Russia, China, and the U.S. maintain a steady demand for this chemical, often sourced through tightly regulated supply chains.
Fuel tablets made from Hexamethylenetetramine (Urotropine) are widely used in military and camping applications due to their clean combustion and ease of storage. Although this is a niche segment, it maintains stable demand across various regions.
The resin and coatings sector uses Hexamethylenetetramine (Urotropine) as a hardening agent in the manufacture of thermosetting resins. The demand is particularly strong in the construction and electronics sectors, where durable and heat-resistant materials are essential.
Water treatment is an emerging application where the compound is used for its biocidal properties. Although small in volume compared to others, this segment is expected to grow in regions with increasing environmental regulation.
Laboratory and industrial reagent usage forms a minor segment, catering mostly to R&D and analytical needs.
By End-Use Industry:
- Automotive
- Chemical Manufacturing
- Pharmaceuticals
- Defense and Aerospace
- Consumer Goods
- Healthcare
Automotive and industrial chemical sectors are dominant consumers due to their reliance on reinforced plastics and resins. The pharmaceutical industry’s demand is growing steadily, driven by increased awareness of urinary tract health treatments.
The defense sector, especially in North America and Eastern Europe, is a consistent end-user due to explosive applications. Meanwhile, healthcare and consumer goods demand is fueled by packaging and antiseptic uses.
By Purity Grade:
- Technical Grade
- Pharmaceutical Grade
- High-Purity (Reagent Grade)
Technical grade dominates in terms of volume, while pharmaceutical and high-purity grades command higher margins due to strict regulatory and quality requirements.
By Distribution Channel:
- Direct Sales
- Distributors
- Online Platforms
Most large-scale buyers source through direct contracts, especially in the industrial and pharmaceutical sectors. Distributors are common for medium-scale buyers across regional markets, particularly in developing economies.
By Geography:
- Asia-Pacific
- Europe
- North America
- Middle East & Africa
- Latin America
Asia-Pacific leads the global market in consumption and production, particularly China and India. Europe follows with specialized demand in pharmaceutical and industrial segments. North America is a stable market with high regulatory standards. The Middle East is an emerging market with growing downstream chemical infrastructure, while Latin America remains a small but steadily growing region.
In conclusion, the Hexamethylenetetramine (Urotropine) market segmentation reveals diverse applications and demand patterns across geographies and industries. Leading segments like plastics, pharmaceuticals, and explosives are expected to drive market growth in the coming years. Factors like quality requirements, regulatory compliance, and downstream integration will continue to influence the segmentation dynamics through 2025 and beyond.